Nuvalent, Inc. NUVL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Nuvalent, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvalent, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvalent, Inc.'s cash & equivalents?
- Nuvalent, Inc. (NUVL) reported cash & equivalents of $159.73M in Q1 2026.
- How has Nuvalent, Inc.'s cash & equivalents changed year-over-year?
- Nuvalent, Inc.'s cash & equivalents increased by 32.2% year-over-year, from $120.84M to $159.73M.
- What is the long-term trend for Nuvalent, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Nuvalent, Inc.'s cash & equivalents has grown at a 90.9% compound annual growth rate (CAGR), from $10.33M to $261.75M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments readily available to the company.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and ability to fund R&D, while a decrease may signal cash burn or the need for future financing.
- How does cash & equivalents compare across companies?
- Peers in the clinical-stage biotech sector typically maintain high cash balances to support multi-year development pipelines.